2 results
Approved WMOWill not start
The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.